Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject ...

Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. <li /> Consistent improve ...

Straumann Dysphagia Index, a patient-reported outcome measure designed ... Using data from four biopsy sites, which is consistent with the FDA Guidance for Developing Drugs for the Treatment of EoE, ...

Although mostly asymptomatic, the retroesophageal and retrotracheal course of the lusorian artery might result in unspecific thoracic pain, dysphagia ... endovascular treatment, and a combined ...

It can make it difficult to eat certain foods, difficult to get adequate nutrients, and generally just difficult to function ...

In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by ...

At this point, a total of 286 patients had received treatment with 360 mg of cendakimab once weekly, and 143 had received placebo. The change in dysphagia days was −6.1 in patients on cendakimab ...

Top quality health care requires a team of skilled professionals working in collaboration with doctors and nurses ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...

Let’s dissect seven multiple sclerosis symptoms that Black people should recognize, and what they can do to address them.

President-elect Donald trump has announced that billionaire Elon Musk and Vivek Ramaswamy, a former presidential candidate ...